PMID- 26189022
OWN - NLM
STAT- MEDLINE
DCOM- 20160721
LR  - 20200711
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 764
DP  - 2015 Oct 5
TI  - Effect of galantamine on adjuvant-induced arthritis in rats.
PG  - 547-553
LID - S0014-2999(15)30164-3 [pii]
LID - 10.1016/j.ejphar.2015.07.038 [doi]
AB  - Stimulation of the vagus nerve suppresses cytokine production and macrophage 
      activation, via the interaction of its neurotransmitter acetylcholine (ACh) with 
      the alpha7 subunit of the nicotinic acetylcholine receptor (alpha7nAChR), present on 
      neurons and inflammatory cells. The present study aimed to verify the potential 
      anti-inflammatory effect of galantamine against experimental arthritis induced in 
      rats. Fourteen days post adjuvant injection, Sprague-Dawley rats were treated 
      orally with three doses of galantamine (1.25, 2.5 and 5 mg/kg) or leflunomide (10 
      mg/kg) for 2 weeks and arthritis progression was assessed by hind paw swelling. 
      Additionally, serum biomarkers, viz., anti-cyclic citrullinated peptide 
      antibodies (Anti-CCP), tumor necrosis factor-alpha (TNF-alpha), interleukin-10 (IL-10) 
      and monocyte chemoattractant protein-1 (MCP-1) were measured. Radiological 
      examination of the hind paws was also carried out to evaluate the degree of joint 
      damage. Adjuvant arthritis led to a significant weight loss, marked swelling of 
      the hind paw and alteration in the serum levels of anti-CCP, TNF-alpha, IL-10 and 
      MCP-1. These alterations were associated with significant radiological changes of 
      the joints. Galantamine, in a dose-dependent manner, reduced significantly all 
      biomarkers of inflammation, with the highest dose showing the best beneficial 
      anti-inflammatory effect that was superior in magnitude to the reference drug 
      leflunomide in most of the studied parameters. In conclusion, these results 
      suggest that galantamine may represent a novel, inexpensive and effective 
      therapeutic strategy in the treatment of rheumatoid arthritis.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Gowayed, Mennatallah A
AU  - Gowayed MA
AD  - Department of Pharmacology, Faculty of Pharmacy and Drug Manufacturing, Pharos 
      University, Alexandria, Egypt.
FAU - Refaat, Rowaida
AU  - Refaat R
AD  - Department of Pharmacology, Medical Research Institute, University of Alexandria, 
      Alexandria, Egypt.
FAU - Ahmed, Walid M
AU  - Ahmed WM
AD  - Department of Radiology, Medical Research Institute, University of Alexandria, 
      Alexandria, Egypt.
FAU - El-Abhar, Hanan S
AU  - El-Abhar HS
AD  - Department of Pharmacology, Faculty of Pharmacy, Cairo University, Kasr El-Aini 
      Street, 11562 Cairo, Egypt. Electronic address: hanan.elabhar@pharma.cu.edu.eg.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150717
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Isoxazoles)
RN  - 0 (Parasympathomimetics)
RN  - 0D3Q044KCA (Galantamine)
RN  - 9007-81-2 (Freund's Adjuvant)
RN  - G162GK9U4W (Leflunomide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Arthritis, Experimental/blood/diagnostic imaging/*drug therapy/immunology
MH  - Biomarkers/blood
MH  - Dose-Response Relationship, Drug
MH  - Freund's Adjuvant
MH  - Galantamine/*pharmacology
MH  - Inflammation Mediators/blood
MH  - Isoxazoles/pharmacology
MH  - Joints/*drug effects/immunology/metabolism/pathology
MH  - Leflunomide
MH  - Male
MH  - Mycobacterium/immunology
MH  - Parasympathomimetics/*pharmacology
MH  - Radiography
MH  - Rats, Sprague-Dawley
MH  - Time Factors
OTO - NOTNLM
OT  - Adjuvant-induced arthritis
OT  - Anti-CCP
OT  - Galantamine
OT  - Galantamine (PubChem CID: 9651)
OT  - IL-10
OT  - Leflunamide (PubChem CID: 3899)
OT  - MCP-1
OT  - Saline (PubChem CID: 5234)
OT  - TNF-alpha
EDAT- 2015/07/21 06:00
MHDA- 2016/07/22 06:00
CRDT- 2015/07/20 06:00
PHST- 2015/04/19 00:00 [received]
PHST- 2015/06/25 00:00 [revised]
PHST- 2015/07/15 00:00 [accepted]
PHST- 2015/07/20 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/07/22 06:00 [medline]
AID - S0014-2999(15)30164-3 [pii]
AID - 10.1016/j.ejphar.2015.07.038 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Oct 5;764:547-553. doi: 10.1016/j.ejphar.2015.07.038. Epub 
      2015 Jul 17.